ES2624288T3 - Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados - Google Patents

Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados Download PDF

Info

Publication number
ES2624288T3
ES2624288T3 ES12702690.4T ES12702690T ES2624288T3 ES 2624288 T3 ES2624288 T3 ES 2624288T3 ES 12702690 T ES12702690 T ES 12702690T ES 2624288 T3 ES2624288 T3 ES 2624288T3
Authority
ES
Spain
Prior art keywords
compound
mixture
formula
jcf
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12702690.4T
Other languages
English (en)
Spanish (es)
Inventor
Branko MITASEV
Dae-Shik Kim
Huiming Zhang
Matthew J. Schnaderback
Christopher N. Farthing
Kazuhiro Yoshizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Application granted granted Critical
Publication of ES2624288T3 publication Critical patent/ES2624288T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES12702690.4T 2011-01-21 2012-01-20 Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados Active ES2624288T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434849P 2011-01-21 2011-01-21
US201161434849P 2011-01-21
PCT/US2012/022053 WO2012100179A1 (en) 2011-01-21 2012-01-20 Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives

Publications (1)

Publication Number Publication Date
ES2624288T3 true ES2624288T3 (es) 2017-07-13

Family

ID=45563570

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12702690.4T Active ES2624288T3 (es) 2011-01-21 2012-01-20 Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados

Country Status (12)

Country Link
US (3) US8426584B2 (enExample)
EP (1) EP2665716B1 (enExample)
JP (2) JP5993875B2 (enExample)
CN (2) CN106632401B (enExample)
BR (1) BR112013016241A2 (enExample)
CA (1) CA2814014A1 (enExample)
ES (1) ES2624288T3 (enExample)
IL (1) IL226405A0 (enExample)
MX (1) MX2013005115A (enExample)
RU (1) RU2013138226A (enExample)
SG (2) SG191710A1 (enExample)
WO (1) WO2012100179A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910143B (zh) 2008-01-18 2013-08-21 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Bace抑制劑
ES2909797T3 (es) * 2014-10-10 2022-05-10 Eisai R&D Man Co Ltd Composición farmacéutica de derivado de aminodihidrotiazina condensado
CN117244056A (zh) 2016-10-27 2023-12-19 卫材研究发展管理有限公司 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
WO2020023530A2 (en) 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227713A (en) 1966-01-04 Azine derivatives
US3235551A (en) 1966-02-15 Novel derivatives of
JPH0967355A (ja) 1995-08-31 1997-03-11 Tokyo Tanabe Co Ltd チアジン誘導体、チアゾール誘導体及びそれらの製造方法
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
US6562783B2 (en) 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
AU2003254844A1 (en) 2002-08-09 2004-02-25 Takeda Chemical Industries, Ltd. Substituted amino compounds and use thereof
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
CA2505098A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005058311A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2007530696A (ja) 2004-03-30 2007-11-01 メルク エンド カムパニー インコーポレーテッド アスパラギン酸プロテアーゼ阻害剤として有用な2−アミノチアゾール化合物
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
EP1802588A4 (en) 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
CN101084199A (zh) 2004-10-15 2007-12-05 阿斯利康(瑞典)有限公司 取代的氨基化合物及其用途
JP2008526999A (ja) 2005-01-19 2008-07-24 メルク エンド カムパニー インコーポレーテッド アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン
AU2006259572A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
EP2004630A4 (en) 2006-04-05 2010-05-19 Astrazeneca Ab 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES RELATED TO PROTEIN A
WO2007139230A1 (ja) 2006-05-31 2007-12-06 Asubio Pharma Co., Ltd. 7員環化合物並びにその製造法および医薬用途
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2008133273A1 (ja) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
WO2008146871A1 (ja) 2007-05-29 2008-12-04 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規1,2,3,4-テトラヒドロキノキサリン誘導体
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
CN101910143B (zh) 2008-01-18 2013-08-21 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
CA2738150A1 (en) 2008-09-30 2010-04-08 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
MX2012015135A (es) 2010-07-01 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives

Also Published As

Publication number Publication date
SG191710A1 (en) 2013-08-30
JP2016121177A (ja) 2016-07-07
WO2012100179A1 (en) 2012-07-26
US8802871B2 (en) 2014-08-12
CN106632401A (zh) 2017-05-10
JP5993875B2 (ja) 2016-09-14
US8426584B2 (en) 2013-04-23
EP2665716A1 (en) 2013-11-27
US20120190848A1 (en) 2012-07-26
RU2013138226A (ru) 2015-02-27
MX2013005115A (es) 2013-06-03
US20130197244A1 (en) 2013-08-01
IL226405A0 (en) 2013-07-31
JP2014503001A (ja) 2014-02-06
JP6087005B2 (ja) 2017-03-01
US8962858B2 (en) 2015-02-24
CN103502231A (zh) 2014-01-08
CN106632401B (zh) 2020-12-29
SG10201601516QA (en) 2016-03-30
US20140309429A1 (en) 2014-10-16
CA2814014A1 (en) 2012-07-26
BR112013016241A2 (pt) 2016-07-12
EP2665716B1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
ES2624288T3 (es) Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados
AU2009205072B2 (en) Condensed aminodihydrothiazine derivative
AU2010270691B8 (en) BACE inhibitors
ES2689526T3 (es) Moduladores de P2X7
JP2021523200A (ja) Magl阻害剤
CA2723207A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
EP3177618A1 (en) Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
JPWO2020241853A5 (enExample)
US20230416252A1 (en) Process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
JP2022511167A (ja) 選択的bace1阻害活性を有する二環式複素環誘導体
KR101950129B1 (ko) N-[3-[(4aR,7aS)-2-아미노-6-(5-플루오로피리미딘-2-일)-4,4a,5,7-테트라히드로피롤로[3,4-d][1,3]티아진-7a-일]-4-플루오로-페닐]-5-메톡시-피라진-2-카르복스아미드의 토실레이트 염
KR101915419B1 (ko) BACE 억제제로서의 테트라히드로피롤로[3,4-d][1,3]티아진-유도체
AU2004289652B2 (en) Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto
WO2014015125A1 (en) Fused aminodihydrothiazine derivative salts and uses thereof
US12351577B2 (en) Inhibiting cyclic AMP-responsive element-binding protein (CREB)
GB2504615A (en) Fused aminodihydrothiazine derivatives
MXPA06005039A (en) Processes for preparing bicyclo [3.1.0]hexane derivatives, and intermediates thereto
MXPA06006148A (en) Process for the preparation of thiazolopyrimidines
MX2008008161A (en) Anti-viral compounds